SCNI (Scinai Immunotherapeutics) Moat Score : 4/10 (As of Jul. 13, 2025)

View and export this data going back to 2015. Start your Free Trial

What is Scinai Immunotherapeutics Moat Score?

Scinai Immunotherapeutics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Scinai Immunotherapeutics has Narrow Moat: Scinai has some valuable intellectual property in immunotherapy and potential regulatory advantages, but lacks strong brand strength or network effects to establish a wider moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Scinai Immunotherapeutics might have Narrow Moat - Discernible but modest moat.

Competitive Comparison of Scinai Immunotherapeutics's Moat Score

For the Biotechnology subindustry, Scinai Immunotherapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scinai Immunotherapeutics's Moat Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Scinai Immunotherapeutics's Moat Score falls into.

Save Embed

;

Save Embed

;

Scinai Immunotherapeutics (NAS:SCNI) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score	Moat Level
10	Wide Moat - Exceptionally dominant and durable wide moat
8 - 9	Wide Moat - Clear and robust wide moat
7	Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6	Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5	Narrow Moat - Solid narrow moat
4	Narrow Moat - Discernible but modest moat
1 - 3	No Moat - Very weak/transient advantages
0	No Moat - No discernible moat

Scinai Immunotherapeutics Moat Score Related Terms

Thank you for viewing the detailed overview of Scinai Immunotherapeutics's Moat Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Scinai Immunotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scinai Immunotherapeutics Ltd (NAS:SCNI) » Definitions » Moat Score

Comparable Companies

Traded in Other Exchanges

2F5:Germany

Address

Hadassah Ein Kerem Campus, 2nd Floor, Jerusalem BioPark, Jerusalem, ISR

Website

https://www.scinai.com

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

Executives

Samuel J Moed	director	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Mark Germain	director, other: Chairman	WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Uri Ben-or	officer: Chief Financial Officer	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Yael Margolin	director	4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Adi Raviv	director	STRAUS CAPITAL GROUP, 411 HACKENSACK AVENUE, 7TH FLOOR, HACKENSACK NJ 07601
Morris C Laster	director	11 REUVEN SHARI ST., JERUSALEM L3 9724611
Tamar Ben-yedidia	officer: Chief Scientist	6 HAZIT ST., MAZKERET BATIA L3 7685421
Avner Rotman	director	21 EISENBERG ST., REHOVOT L3 7628905
Amir Reichman	director, officer: Chief Executive Officer	269 NAHAL FARAN ST., TAL SHAHAR L3 7680500
Elad Mark	officer: Chief Operating Officer	27 HAILANOT, HERZLIYA L3 4631214
George Lowell	director	33 DERECH BEIT LECHEM ST., JERUSALEM L3 9355317
Jay Green	director	354 CONCESSION 10 E, FREELTON, ON Z4 L8B 1H6